Dr. Kim is the founder and CEO of TCUBEit which focuses on innovative T cell-based immuno-therapy. He has worked on adoptive T cell therapy, molecular recognition in the immune system, and antibody drug development with over 20 years of T cell immunology field experience.

Before TCUBEit, he served as the CTO and Co-Founder of the M5 Bioscience Group, a Principal Scientist at Medytox Inc., and worked as an Invited Scientist of T Cell Biology for the Korea Research Institute of Bioscience and Biotechnology (KRIBB). He has initiated and led multiple drug development projects on autoimmunity and immuno-oncology as the principal investigator in both academia and the biopharmaceutical industry.

Dr. Kim received his Ph.D. from Korea Advanced Institute of Science Technology (KAIST) in immunology and biophysics. During his Ph.D. program, he studied antibody engineering and structure modeling at the Biomolecular Engineering Research Institute in Osaka, Japan. He worked as an instructor at the Dana-Farber Cancer Institute and Harvard Medical School, investigating the molecular architecture and signaling mechanism of the T cell receptor (TCR) and CD3 subunits.

Dr. Kang is an advisory member of TCUBEit. He is currently working as an Associate Professor in the Department of Biomedical Science, Jungwon University, South Korea. He received his Ph.D. in Molecular Biology and Immunology from Kyungpook National University, South Korea. He performed his postdoctoral research in the biology of CD8 using animal model systems at the Department of Medicine, Harvard Medical School, U.S.

He has extensive research experience as a research scientist at the Cancer Vaccine Center of Dana-Farber Cancer Institute and Harvard Medical School, where he led research to identify novel T cell epitopes in multiple myeloma. His research encompasses several immunological areas such as the screening of tumor antigens, T cell therapy, the biology of CD8 molecules, cytokines, and nanoparticle-mediated antigen delivery to study effective cancer therapy.

Dr. Lee is an advisory member of TCUBEit. He is serving as the CEO of Speegen Bio Inc., which develops diagnostic tools for infectious diseases. He worked as a Postdoctoral Associate at both Massachusetts General Hospital and Harvard Medical School, then serving as a Senior Biological Scientist at the University of Florida. During his stay in the U.S., he studied how iNKT cells play a role in regulatory T cell generation which recover autoimmune diseases, i.e, Type I diabetes, rheumatoid arthritis, Lyme disease, systemic lupus erythematosus, and autoimmune pancreatitis, etc.

He received his B.S, M.S., and Ph.D. in Microbiology and Molecular Biology from Kyung Hee University, South Korea. He served as a research fellow developing diagnostic tools and vaccines for the Korea Center for Disease Control for over ten years. In addition, he developed a new strategy to treat AIDS patients based on gene therapy.

Dr. Baek is an advisory member of TCUBEit. He is a professor of Microbiology at the Keimyung University School of Medicine located in South Korea. He is also serving as a board member on the Korean Cancer Research Association, NRF and KHIDI.

He received his M.D. and Ph. D. from Keimyung University. He worked as a visiting scientist at the Dana-Farber Cancer Institute and Harvard Medical School in research projects focused on cancer genomics and drug development. He has extensive research experience in the field of cancer therapeutics studying how autophagy can promote cell survival in human brain cancer and how ROS plays a role in cell death.